6-[5-(2,4-bistrifluoromethylbenzoylamino)pyridin-2-yloxy]-1-methyl-1H-indole-2-carboxylic acid | 1150744-89-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6-[5-(2,4-bistrifluoromethylbenzoylamino)pyridin-2-yloxy]-1-methyl-1H-indole-2-carboxylic acid
• 英文别名: 6-[5-[[2,4-Bis(trifluoromethyl)benzoyl]amino]pyridin-2-yl]oxy-1-methylindole-2-carboxylic acid
• CAS: 1150744-89-0
• 化学式: C₂₄H₁₅F₆N₃O₄
• 分子量: 523.391
• InChiKey: QVYNNSHJMKOUAT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  37
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  93.4
• 氢给体数：
  2
• 氢受体数：
  11

文献信息

• HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF
  申请人：Sumida Takumi

  公开号：US20100261720A1

  公开（公告）日：2010-10-14

  The present invention provides a heterocyclic compound represented by General Formula (1): wherein R 1 is a group R 5 —Z 1 —, etc., Z 1 is a lower alkylene group, etc., and R 5 is a group represented by General Formula; wherein R 13 is a hydrogen atom, etc., m is an integer from 1 to 5; R 2 is a hydrogen atom: Y is CH or N: A 1 is a heterocyclic ring selected from the group consisting of indolediyl groups, wherein the heterocyclic ring may have at least one substituent: T is a group —CO—, etc.: R 3 is a hydrogen atom, etc.: R 4 is a lower alkyl group optionally substituted by one or more hydroxy groups, etc.: R 3 and R 4 , together with the nitrogen atom to which they bind, may bind to each other and form a 5- to 10-membered saturated heterocyclic ring, wherein the heterocyclic ring may have at least one substituent. The heterocyclic compound of the present invention has excellent effects of suppressing the production of collagen and/or treating tumors.

  本发明提供一种由通式(1)表示的杂环化合物：其中R1为R5-Z1-等基团，Z1为低碳烷基等，而R5则为通式所表示的基团；其中R13为氢原子等，m为1到5的整数；R2为氢原子；Y为CH或N；A1为选自吲哚二基基团等的杂环环；其中该杂环环可以具有至少一个取代基；T为-CO-等基团；R3为氢原子等；R4为低碳基基团，可以选择性地被一个或多个羟基取代等；R3和R4与它们所结合的氮原子一起可以结合成一个5-到10-成员的饱和杂环环，其中该杂环环可以具有至少一个取代基。本发明的杂环化合物具有抑制胶原蛋白产生和/或治疗肿瘤的优异效果。
• US8551999B2
  申请人：——

  公开号：US8551999B2

  公开（公告）日：2013-10-08
• [EN] HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF<br/>[FR] COMPOSÉ HÉTÉROCYCLIQUE ET COMPOSITION PHARMACEUTIQUE CONTENANT LEDIT COMPOSÉ
  申请人：OTSUKA PHARMA CO LTD

  公开号：WO2009057811A2

  公开（公告）日：2009-05-07

  The present invention provides a heterocyclic compound represented by General Formula (1): wherein R1 is a group R5-Z1-, etc., Z1 is a lower alkylene group, etc., and R5 is a group represented by General Formula; wherein R13 is a hydrogen atom, etc., m is an integer from 1 to 5; R2 is a hydrogen atom: Y is CH or N: A1 is a heterocyclic ring selected from the group consisting of indolediyl groups, wherein the heterocyclic ring may have at least one substituent: T is a group -CO-, etc.: R3 is a hydrogen atom, etc.: R4 is a lower alkyl group optionally substituted by one or more hydroxy groups, etc.: R3 and R4, together with the nitrogen atom to which they bind, may bind to each other and form a 5- to 10-membered saturated heterocyclic ring, wherein the heterocyclic ring may have at least one substituent. The heterocyclic compound of the present invention has excellent effects of suppressing the production of collagen and/or treating tumors.